Praluent Market Report 2026

Praluent Market Overview

• The Praluent market growth in the historic period has been driven by rising prevalence of hypercholesterolemia, limitations of statin-only therapies • Market expansion is supported by rising focus on aggressive lipid lowering strategies, increasing adoption in secondary prevention • Growth Driver: Rising Obesity Rates Drive Growth In The Market • Market Trend: Advancements In Personalized Medicine Driving Innovation In Cholesterol Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Praluent Market?

Praluent is a monoclonal antibody used to treat high cholesterol levels, specifically low-density lipoprotein (LDL) cholesterol, known as bad cholesterol. It is used for treating adults with primary hypercholesterolemia or mixed dyslipidemia and reducing cardiovascular risk in patients with established heart disease. The main indications for praluent are primary hypercholesterolemia, mixed dyslipidemia, and established atherosclerotic cardiovascular disease (ASCVD). Primary hypercholesterolemia is a genetic condition marked by elevated levels of LDL cholesterol in the blood. Praluent, which contains alirocumab, treats this condition by blocking the PCSK9 protein, thereby reducing LDL cholesterol levels. It is distributed through various channels such as hospitals and clinics, retail pharmacies, and specialty pharmacies and is utilized by end users including ambulatory care and homecare.

What Is The Praluent Market Growth Forecast?

The growth in the forecast period can be attributed to rising focus on aggressive lipid lowering strategies, increasing adoption in secondary prevention, expansion of value-based cardiovascular care, growing payer support for pcsk9 inhibitors, increasing awareness of cardiovascular risk reduction. Major trends in the forecast period include increasing use of pcsk9 inhibitors in lipid management, rising adoption in high-risk cardiovascular patients, growing integration with statin combination therapy, expansion of preventive cardiology programs, enhanced focus on long-term ldl control.

Global Praluent Market Segmentation

1) By Indication: Primary Hypercholesterolemia, Mixed Dyslipidemia, Established Atherosclerotic Cardiovascular Disease (ASCVD) 2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies 3) By End-User: Ambulatory Care, Home Care

What Are The Drivers Of The Praluent Market?

The rise in obesity is expected to propel the growth of the praluent market going forward. Obesity refers to a medical condition characterized by excessive body fat accumulation that poses a risk to health, typically defined by a Body Mass Index (BMI) of 30 or higher. The rising prevalence of obesity is largely attributed to shifts in global food systems and eating habits, characterized by increased consumption of ultra-processed foods, sedentary lifestyles, and economic factors that make unhealthy food choices more readily available. Praluent helps obesity by reducing LDL cholesterol levels in individuals with obesity-related dyslipidemia, as it is a PCSK9 inhibitor that enhances the liver's ability to remove LDL cholesterol from the blood, thereby improving cardiovascular health and reducing obesity-related complications. For instance, in May 2024, according to a report published by the Office for Health Improvement and Disparities, a UK-based government department responsible for maintaining public health policies, 64.0% of adults (18+) in England were estimated to be overweight or living with obesity in the period 2022–2023, while 26.2% were estimated to be living with obesity (BMI ≥ 30 kg/m²). Therefore, the rise in obesity will drive the growth of the praluent industry forward. Increasing adoption of personalized medicine is expected to propel the growth of the Praluent market going forward. Personalized medicine refers to a treatment approach in which clinicians tailor therapies to individual biological characteristics to improve clinical outcomes. Adoption of personalized medicine is rising because clinicians increasingly prefer therapies that align with genetic and biomarker profiles to achieve greater treatment precision. Praluent supports the increasing adoption of personalized medicine because clinicians can use its targeted PCSK9-inhibiting mechanism to tailor LDL-cholesterol reduction to individual cardiovascular-risk profiles. For instance, in February 2025, according to BioSpace, Inc., a U.S.-based life science news site, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, increasing adoption of personalized medicine is expected to drive the growth of the Praluent industry.

Key Players In The Global Praluent Market

Major companies operating in the praluent market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

Global Praluent Market Trends and Insights

Major companies operating in the praluent market are focusing on developing innovative solutions, such as low-density lipoprotein cholesterol (LDL-C) lowering therapies, to meet the rising demand for advanced cardiovascular risk-reduction treatments. LDL-C–lowering therapies are specialized medical interventions designed to significantly reduce levels of “bad cholesterol,” offering more precise, targeted, and sustained lipid control compared to traditional statins or lifestyle modifications alone. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) extended approval for Praluent (alirocumab) injection, an advanced LDL-C–lowering biologic therapy. This updated approval allows its use as an add-on to diet and existing lipid-lowering treatments for pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). Praluent is a PCSK9 inhibitor monoclonal antibody designed to increase LDL receptor availability, resulting in marked and sustained LDL-C reduction. The therapy offers high efficacy, favorable safety, and less frequent dosing compared to many traditional lipid-lowering options. By extending access to children with genetic high cholesterol, the product helps address early-onset cardiovascular risk and supports long-term heart health management.

Regional Insights

North America was the largest region in the praluent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Praluent Market?

The praluent market consists of sales of praluent (alirocumab) injection and one per-filled pen. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Praluent Market Report 2026?

The praluent market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the praluent industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.